NovAliX, a Strasbourg, France-based preclinical contract research organization (CRO) specializing in expert drug discovery services, received an investment from Bruker (Nasdaq: BRKR).
The amount oof the deal was not disclosed.
The company intends to use the funds to accelerate the growth and further expansion, particularly within Europe and the United States.
Led by Stephan Jenn, President, NovAliX is a company which specializes in drug discovery, combining biophysics, medicinal chemistry, and pharmacology. Their advanced biophysics platform supports drug discovery from target assessment to lead optimization. NovAliX has a highly scientific and technical workforce with over 430 employees, distributed across its European R&D and CRO service sites and an additional medicinal chemistry North-African site.
Bruker and NovAliX will partner on advancing functional structural biology, biophysical methods for characterizing molecular dynamics and interactions, biocondensates and aggregation, drug candidate binding, therapeutic mechanisms of action (MoA), and elucidating potential off-target effects.
Looking ahead, Bruker and NovAliX also plan to conduct joint innovation activities through the Biophysics Institute for Biomedical Research (IBRB) in Strasbourg. This new institute, set to open in 2026, will host biotechs, start-ups, and academic groups, fostering collaboration and innovation in the field of biophysics and drug discovery.
FinSMEs
08/08/2024